|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC25A6 |
Gene summary for SLC25A6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC25A6 | Gene ID | 293 |
| Gene name | solute carrier family 25 member 6 | |
| Gene Alias | AAC3 | |
| Cytomap | X | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | P12236 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 293 | SLC25A6 | GSM4909280 | Human | Breast | Precancer | 9.92e-04 | -6.90e-01 | 0.0305 |
| 293 | SLC25A6 | GSM4909282 | Human | Breast | IDC | 9.95e-15 | 2.97e-01 | -0.0288 |
| 293 | SLC25A6 | GSM4909286 | Human | Breast | IDC | 1.01e-07 | 2.80e-01 | 0.1081 |
| 293 | SLC25A6 | GSM4909291 | Human | Breast | IDC | 2.78e-15 | 3.41e-01 | 0.1753 |
| 293 | SLC25A6 | GSM4909292 | Human | Breast | IDC | 3.31e-05 | -8.68e-01 | 0.1236 |
| 293 | SLC25A6 | GSM4909293 | Human | Breast | IDC | 1.22e-37 | -4.21e-01 | 0.1581 |
| 293 | SLC25A6 | GSM4909294 | Human | Breast | IDC | 6.39e-10 | -3.36e-01 | 0.2022 |
| 293 | SLC25A6 | GSM4909295 | Human | Breast | IDC | 1.56e-02 | -3.77e-01 | 0.0898 |
| 293 | SLC25A6 | GSM4909296 | Human | Breast | IDC | 1.20e-15 | 2.25e-01 | 0.1524 |
| 293 | SLC25A6 | GSM4909297 | Human | Breast | IDC | 8.98e-32 | -5.45e-01 | 0.1517 |
| 293 | SLC25A6 | GSM4909298 | Human | Breast | IDC | 8.63e-06 | -8.26e-02 | 0.1551 |
| 293 | SLC25A6 | GSM4909299 | Human | Breast | IDC | 1.03e-06 | -1.90e-01 | 0.035 |
| 293 | SLC25A6 | GSM4909301 | Human | Breast | IDC | 7.46e-45 | -7.86e-01 | 0.1577 |
| 293 | SLC25A6 | GSM4909302 | Human | Breast | IDC | 1.11e-12 | -5.37e-01 | 0.1545 |
| 293 | SLC25A6 | GSM4909304 | Human | Breast | IDC | 8.19e-17 | -2.52e-01 | 0.1636 |
| 293 | SLC25A6 | GSM4909305 | Human | Breast | IDC | 9.20e-03 | 1.82e-01 | 0.0436 |
| 293 | SLC25A6 | GSM4909306 | Human | Breast | IDC | 1.91e-02 | 2.24e-01 | 0.1564 |
| 293 | SLC25A6 | GSM4909308 | Human | Breast | IDC | 2.28e-10 | -8.27e-03 | 0.158 |
| 293 | SLC25A6 | GSM4909311 | Human | Breast | IDC | 4.93e-42 | -4.00e-01 | 0.1534 |
| 293 | SLC25A6 | GSM4909312 | Human | Breast | IDC | 2.63e-02 | -1.66e-02 | 0.1552 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00068398 | Breast | Precancer | mitochondrial transport | 45/1080 | 254/18723 | 1.37e-11 | 1.88e-09 | 45 |
| GO:19905427 | Breast | Precancer | mitochondrial transmembrane transport | 22/1080 | 102/18723 | 6.38e-08 | 3.80e-06 | 22 |
| GO:000683913 | Breast | IDC | mitochondrial transport | 51/1434 | 254/18723 | 1.54e-10 | 1.83e-08 | 51 |
| GO:199054214 | Breast | IDC | mitochondrial transmembrane transport | 25/1434 | 102/18723 | 1.39e-07 | 7.74e-06 | 25 |
| GO:000683923 | Breast | DCIS | mitochondrial transport | 51/1390 | 254/18723 | 5.04e-11 | 6.79e-09 | 51 |
| GO:199054222 | Breast | DCIS | mitochondrial transmembrane transport | 25/1390 | 102/18723 | 7.63e-08 | 4.45e-06 | 25 |
| GO:00068399 | Cervix | CC | mitochondrial transport | 60/2311 | 254/18723 | 4.21e-07 | 1.67e-05 | 60 |
| GO:19905428 | Cervix | CC | mitochondrial transmembrane transport | 26/2311 | 102/18723 | 2.10e-04 | 2.39e-03 | 26 |
| GO:00159318 | Cervix | CC | nucleobase-containing compound transport | 43/2311 | 222/18723 | 1.72e-03 | 1.30e-02 | 43 |
| GO:000683914 | Cervix | HSIL_HPV | mitochondrial transport | 22/737 | 254/18723 | 4.72e-04 | 6.90e-03 | 22 |
| GO:199054215 | Cervix | HSIL_HPV | mitochondrial transmembrane transport | 12/737 | 102/18723 | 6.67e-04 | 9.08e-03 | 12 |
| GO:0015867 | Cervix | HSIL_HPV | ATP transport | 4/737 | 17/18723 | 3.76e-03 | 3.30e-02 | 4 |
| GO:0006839 | Colorectum | AD | mitochondrial transport | 102/3918 | 254/18723 | 1.87e-12 | 3.08e-10 | 102 |
| GO:1990542 | Colorectum | AD | mitochondrial transmembrane transport | 47/3918 | 102/18723 | 1.09e-08 | 6.52e-07 | 47 |
| GO:0015931 | Colorectum | AD | nucleobase-containing compound transport | 73/3918 | 222/18723 | 2.02e-05 | 4.10e-04 | 73 |
| GO:0015748 | Colorectum | AD | organophosphate ester transport | 42/3918 | 140/18723 | 7.04e-03 | 4.31e-02 | 42 |
| GO:00068391 | Colorectum | SER | mitochondrial transport | 87/2897 | 254/18723 | 7.91e-14 | 3.03e-11 | 87 |
| GO:19905421 | Colorectum | SER | mitochondrial transmembrane transport | 42/2897 | 102/18723 | 3.65e-10 | 4.77e-08 | 42 |
| GO:00159311 | Colorectum | SER | nucleobase-containing compound transport | 54/2897 | 222/18723 | 3.65e-04 | 5.67e-03 | 54 |
| GO:00068392 | Colorectum | MSS | mitochondrial transport | 93/3467 | 254/18723 | 6.14e-12 | 9.82e-10 | 93 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa0501714 | Breast | Precancer | Spinocerebellar ataxia | 29/684 | 143/8465 | 2.79e-06 | 3.83e-05 | 2.94e-05 | 29 |
| hsa042189 | Breast | Precancer | Cellular senescence | 29/684 | 156/8465 | 1.66e-05 | 1.69e-04 | 1.30e-04 | 29 |
| hsa0516618 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
| hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa0501715 | Breast | Precancer | Spinocerebellar ataxia | 29/684 | 143/8465 | 2.79e-06 | 3.83e-05 | 2.94e-05 | 29 |
| hsa0421814 | Breast | Precancer | Cellular senescence | 29/684 | 156/8465 | 1.66e-05 | 1.69e-04 | 1.30e-04 | 29 |
| hsa0516619 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC25A6 | SNV | Missense_Mutation | novel | c.213N>T | p.Trp71Cys | p.W71C | P12236 | protein_coding | deleterious(0.02) | probably_damaging(0.967) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| SLC25A6 | SNV | Missense_Mutation | novel | c.88N>C | p.Glu30Gln | p.E30Q | P12236 | protein_coding | deleterious(0.02) | possibly_damaging(0.9) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC25A6 | insertion | Frame_Shift_Ins | novel | c.257_258insATCCTCTCTTCTTATGGGATGTCTTAAT | p.Leu87SerfsTer17 | p.L87Sfs*17 | P12236 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SLC25A6 | SNV | Missense_Mutation | novel | c.273N>G | p.Phe91Leu | p.F91L | P12236 | protein_coding | deleterious(0.03) | possibly_damaging(0.503) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC25A6 | SNV | Missense_Mutation | novel | c.88N>A | p.Glu30Lys | p.E30K | P12236 | protein_coding | tolerated(0.07) | possibly_damaging(0.775) | TCGA-VS-A9V3-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| SLC25A6 | SNV | Missense_Mutation | novel | c.132N>C | p.Gln44His | p.Q44H | P12236 | protein_coding | deleterious(0.03) | benign(0.185) | TCGA-VS-A9V5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| SLC25A6 | SNV | Missense_Mutation | c.793N>A | p.Glu265Lys | p.E265K | P12236 | protein_coding | deleterious(0.02) | possibly_damaging(0.677) | TCGA-AD-6963-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SLC25A6 | SNV | Missense_Mutation | novel | c.36C>A | p.Phe12Leu | p.F12L | P12236 | protein_coding | tolerated(0.4) | benign(0.038) | TCGA-G4-6297-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | fluorouracil | PD |
| SLC25A6 | SNV | Missense_Mutation | c.365C>T | p.Ala122Val | p.A122V | P12236 | protein_coding | deleterious(0.02) | benign(0.331) | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR | |
| SLC25A6 | SNV | Missense_Mutation | c.55G>C | p.Ala19Pro | p.A19P | P12236 | protein_coding | deleterious(0.02) | possibly_damaging(0.861) | TCGA-AH-6903-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fu | CR |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 293 | SLC25A6 | TRANSPORTER, DRUGGABLE GENOME | CLODRONATE | CLODRONIC ACID |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |